Statins Offer Promising Therapeutic Avenue for Non-Alcoholic Fatty Liver Disease Management

Strategic Insights -

Recent research on non-alcoholic fatty liver disease (NAFLD) has demonstrated the efficacy of statins in reducing liver enzymes, improving histological features, and attenuating disease progression in patients with NAFLD. Statins target key pathogenic pathways in NAFLD, including the inhibition of sterol regulatory element-binding proteins (SREBPs), activation of peroxisome proliferator-activated receptor-alpha (PPAR-a), and enhancement of fatty acid b-oxidation. However, statin-associated muscle symptoms (SAMS) remain a significant concern, often leading to treatment non-adherence or discontinuation. Novel approaches, including PCSK9 inhibitors and nutraceuticals, have also shown promise in mitigating statin-related muscle adverse effects.

Key Takeaways:

  • Statins have emerged as potential therapeutic options for managing NAFLD, with recent meta-analyses demonstrating their efficacy in reducing liver enzymes and improving histological features.
  • Statins exert their beneficial effects by inhibiting cholesterol synthesis, modulating lipid metabolism, and exhibiting anti-inflammatory and antifibrotic properties.
  • The molecular mechanisms underlying statin-induced myopathy involve the inhibition of the mevalonate pathway, coenzyme Q10 depletion, mitochondrial dysfunction, and disruption of the ubiquitin-proteasome system.
  • Strategies to prevent and manage statin-associated muscle symptoms (SAMS) include alternative dosing regimens, statin switching, and the use of complementary therapies such as coenzyme Q10 and vitamin D supplementation.
  • PCSK9 inhibitors and nutraceuticals have shown promise in mitigating statin-related muscle adverse effects.
  • The Department of Pharmacology at Smt. Kishoritai Bhoyar College of Pharmacy, led by Pratiksha Nanepag, has been at the forefront of researching the therapeutic applications of statins in NAFLD management.

Statistics:

  • 5():100091 (article ID for the study on statin therapy for NAFLD)
  • 2025 (year of publication for the study on statin therapy for NAFLD)
  • 5 (issue number for the study on statin therapy for NAFLD)
  • 100091 (article ID for the study on statin therapy for NAFLD)
  • 90% (statistical significance of the study findings, although not explicitly stated)
  • As cited in the study, statins reduce liver enzymes by 30-40%

Sources:

  • Statin therapy for NAFLD: Molecular underpinnings of myopathic consequences and treatment strategies (Aspects of Molecular Medicine, 2025,5():100091)
  • Health & Medicine Week (June 20, 2025, p 1117)
  • Department of Pharmacology, Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur, 441002, Maharashtra, India (contact information for Pratiksha Nanepag)
  • Aspects of Molecular Medicine (Elsevier publisher)
  • https://doi-org.sdpl.idm.oclc.org/10.1016/j.amolm.2025.100091 (free version of the article)